136 related articles for article (PubMed ID: 19540329)
21. Identification of drugs inducing phospholipidosis by novel in vitro data.
Muehlbacher M; Tripal P; Roas F; Kornhuber J
ChemMedChem; 2012 Nov; 7(11):1925-34. PubMed ID: 22945602
[TBL] [Abstract][Full Text] [Related]
22. Monitoring the accumulation of fluorescently labeled phospholipids in cell cultures provides an accurate screen for drugs that induce phospholipidosis.
Nioi P; Pardo ID; Snyder RD
Drug Chem Toxicol; 2008; 31(4):515-28. PubMed ID: 18850360
[TBL] [Abstract][Full Text] [Related]
23. The phospholipidosis-lnducing potential of the chemopotentiating drug, N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE, tesmilifene) correlates with its stimulation of phosphatidylserine synthesis and exposure on the plasma membrane in MCF-7 breast cancer cells.
Xu FY; Queen G; Brandes L; Hatch GM
Proc West Pharmacol Soc; 2007; 50():61-3. PubMed ID: 18605231
[TBL] [Abstract][Full Text] [Related]
24. Effects of hydroxypyridinone iron chelators in combination with antimalarial drugs on the in vitro growth of Plasmodium falciparum.
Pattanapanyasat K; Kotipun K; Yongvanitchit K; Hider RC; Kyle DE; Heppner DG; Walsh DS
Southeast Asian J Trop Med Public Health; 2001 Mar; 32(1):64-9. PubMed ID: 11485097
[TBL] [Abstract][Full Text] [Related]
25. Basic 3-hydroxypyridin-4-ones: potential antimalarial agents.
Dehkordi LS; Liu ZD; Hider RC
Eur J Med Chem; 2008 May; 43(5):1035-47. PubMed ID: 17869385
[TBL] [Abstract][Full Text] [Related]
26. Evaluating the risk of phospholipidosis using a new multidisciplinary pipeline approach.
Goracci L; Buratta S; Urbanelli L; Ferrara G; Di Guida R; Emiliani C; Cross S
Eur J Med Chem; 2015 Mar; 92():49-63. PubMed ID: 25544686
[TBL] [Abstract][Full Text] [Related]
27. Potent antimalarial 4-pyridones with improved physico-chemical properties.
Bueno JM; Manzano P; García MC; Chicharro J; Puente M; Lorenzo M; García A; Ferrer S; Gómez RM; Fraile MT; Lavandera JL; Fiandor JM; Vidal J; Herreros E; Gargallo-Viola D
Bioorg Med Chem Lett; 2011 Sep; 21(18):5214-8. PubMed ID: 21824778
[TBL] [Abstract][Full Text] [Related]
28. Liposome electrokinetic chromatography based in vitro model for early screening of the drug-induced phospholipidosis risk.
Wang T; Feng Y; Jin X; Fan X; Crommen J; Jiang Z
J Pharm Biomed Anal; 2014 Aug; 96():263-71. PubMed ID: 24814828
[TBL] [Abstract][Full Text] [Related]
29. Membrane perturbing properties of natural phenolic and resorcinolic lipids.
Stasiuk M; Kozubek A
FEBS Lett; 2008 Oct; 582(25-26):3607-13. PubMed ID: 18834885
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological activity of new potential antimalarial: 1H-pyrazolo[3,4-b]pyridine derivatives.
Dias LR; Freitas AC; Barreiro EJ; Goins DK; Nanayakkara D; McChesney JD
Boll Chim Farm; 2000; 139(1):14-20. PubMed ID: 10829547
[TBL] [Abstract][Full Text] [Related]
31. Dithionite quenching rate measurement of the inside-outside membrane bilayer distribution of 7-nitrobenz-2-oxa-1,3-diazol-4-yl-labeled phospholipids.
Angeletti C; Nichols JW
Biochemistry; 1998 Oct; 37(43):15114-9. PubMed ID: 9790674
[TBL] [Abstract][Full Text] [Related]
32. Antimalarial activity of 4-(5-trifluoromethyl-1H-pyrazol-1-yl)-chloroquine analogues.
Cunico W; Cechinel CA; Bonacorso HG; Martins MA; Zanatta N; de Souza MV; Freitas IO; Soares RP; Krettli AU
Bioorg Med Chem Lett; 2006 Feb; 16(3):649-53. PubMed ID: 16257205
[TBL] [Abstract][Full Text] [Related]
33. Biochemical and functional analysis of rat bronchoalveolar macrophages containing chemically induced phospholipid inclusions.
Waites CR; Bugelski PJ; Badger AM
Toxicol Appl Pharmacol; 1995 Feb; 130(2):316-21. PubMed ID: 7871542
[TBL] [Abstract][Full Text] [Related]
34. Cellular responses associated with dibucaine-induced phospholipidosis.
Peropadre A; Fernández Freire P; Herrero O; Pérez Martín JM; Hazen MJ
Chem Res Toxicol; 2011 Feb; 24(2):185-92. PubMed ID: 21261262
[TBL] [Abstract][Full Text] [Related]
35. In vitro assays and biomarkers for drug-induced phospholipidosis.
Monteith DK; Morgan RE; Halstead B
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
[TBL] [Abstract][Full Text] [Related]
36. In vitro validation of drug-induced phospholipidosis.
Park S; Choi YJ; Lee BH
J Toxicol Sci; 2012; 37(2):261-7. PubMed ID: 22467016
[TBL] [Abstract][Full Text] [Related]
37. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential.
Kasahara T; Tomita K; Murano H; Harada T; Tsubakimoto K; Ogihara T; Ohnishi S; Kakinuma C
Toxicol Sci; 2006 Mar; 90(1):133-41. PubMed ID: 16338956
[TBL] [Abstract][Full Text] [Related]
38. Cationic amphiphilic drug-induced phospholipidosis.
Halliwell WH
Toxicol Pathol; 1997; 25(1):53-60. PubMed ID: 9061852
[TBL] [Abstract][Full Text] [Related]
39. Inhaled cationic amphiphilic drug-induced pulmonary phospholipidosis in rats and dogs: time-course and dose-response of biomarkers of exposure and effect.
Pauluhn J
Toxicology; 2005 Feb; 207(1):59-72. PubMed ID: 15590122
[TBL] [Abstract][Full Text] [Related]
40. Modeling phospholipidosis induction: reliability and warnings.
Goracci L; Ceccarelli M; Bonelli D; Cruciani G
J Chem Inf Model; 2013 Jun; 53(6):1436-46. PubMed ID: 23692521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
